To the Editor In the article by Lu and colleagues recently published in JAMA Oncology,1 the mutation yield of the genetic analysis of 9639 patients with breast cancer is presented. The mutation prevalence estimates among cases and controls are used to generate odds ratios (ORs) and confidence intervals for each of 625 genes. For example, the OR for the ATM gene is 3.07 (95% CI, 1.60-6.19) and that for the CHEK2 gene is 2.73 (95% CI, 1.67 to –4.61). The reader is tempted to use these ORs as multipliers when calculating lifetime risk for carriers (eg, if we suppose a baseline breast cancer risk of 9% through age 80 years, the corresponding risk estimates would be 28% for the ATM gene and 25% for the CHEK2 gene, and surgical intervention might be justified).